Doramapimod (BIRB 796)

Catalog No.S1574

For research use only.

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Doramapimod (BIRB 796) Chemical Structure

CAS No. 285983-48-4

Selleck's Doramapimod (BIRB 796) has been cited by 93 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Other p38 MAPK Products

Biological Activity

Description Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
Features The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Targets
JNK2 [1]
()
c-RAF [1]
()
Fyn [1]
()
p38α [1]
(Cell-free assay)
p38α [7]
()
0.1 nM(Kd) 38 nM
In vitro

BIRB 796 shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. BIRB 796 greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. BIRB 796 represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. [1] BIRB 796 potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. [2] BIRB796 also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. BIRB796 blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of BIRB796 to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. [3] BIRB 796 blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. BIRB 796 downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. [4] BIRB-796 has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. BIRB-796 also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-92 NH7TbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPwWFhFUUN3ME2yOE4{QDN6IN88US=> M1K4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H2228 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzBOZVKSzVyPUKzMlY3PjhizszN MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
CAPAN-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG3TWM2OD1{Mj6xPFg1KM7:TR?= M3XJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SK-MEL-1 NYj6[lhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvpRotKSzVyPUKwMlM3QDNizszN MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
DB NWnYSHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvtTWM2OD1zOD63PVI{KM7:TR?= MoH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
AN3-CA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXUd|M2UUN3ME2xPE4yKM7:TR?= NIj6Um89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
EW-13 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF5Lkm1NVYh|ryP NVrNUXZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
LC-2-ad MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF5LkSzOlYh|ryP NWfDfI9iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
ES8 NG[zVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXjcXczUUN3ME2xO{4yPjdizszN MmDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H1581 M2L6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHKTWM2OD1zNz6wOFQ4KM7:TR?= NEjndoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HMV-II M4foZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfFTWM2OD1zND6yN|A6KM7:TR?= M3Xl[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
BEN M3zPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXZbmZFUUN3ME2xN{4yOjZ2IN88US=> NXHRUWtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NBsusSR NYX5fZJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnLfHlkUUN3ME2xNE45OjN3IN88US=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
MS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzLTWM2OD1zMD64NlM2KM7:TR?= NInwWJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
BFTC-905 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13lNWlEPTB;MUCuNVI{OyEQvF2= NYrkVpk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1 NEHBXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzL[mcxUUN3ME25MlA3PzN7IN88US=> NGXKcXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
MPP-89 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXjPIFKSzVyPUiuOFYzPTFizszN NWrXVGl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
T-24 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\MRpJKSzVyPUiuOFA3PzNizszN NVS1PIlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
KP-N-YN M17Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRThwMkCxPUDPxE1? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
IST-MES1 NWDsVHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdwOUW2N|ch|ryP NUHpboEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-H358 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKw[ot[UUN3ME23MlU{QCEQvF2= NVzHc5puRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
GOTO NV2xbFE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXnSoNxUUN3ME22MlM6OTZzIN88US=> NV\MO2xIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
DU-145 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNwOUO4NVEh|ryP NGTWPVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
EoL-1-cell MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHNeVNIUUN3ME2wMlM1PzZ|IN88US=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KYSE-270 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnwTWM2OD1{ND61OVc{KM7:TR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HCC1806 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ2Lke3PVkh|ryP M2rjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HuO-3N1 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Lem1KSzVyPUK1MlgyQDVizszN NFTuVIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HOS NXzXXZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrwTnNwUUN3ME2yOU46Ojl{IN88US=> NUizWJFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
KYSE-510 NIjXe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\sO2lEPTB;Mk[uNVYyOiEQvF2= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
COLO-741 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;2bldlUUN3ME2yOk4{OzJ7IN88US=> M4jON|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
H-EMC-SS NVTXSZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq1cVVDUUN3ME2yOk46OjR3IN88US=> NF3leFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HCC1937 NVXnRZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\JTWM2OD1{Nz6yNlM5KM7:TR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H2126 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjhXphKSzVyPUK3MlM6PzVizszN M{[3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H1703 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PKXGlEPTB;MkiuNFQyOyEQvF2= MlXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
U-2-OS MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTVTWM2OD1{OD61OVE2KM7:TR?= NFrEOWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
DBTRG-05MG M{\2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\YZow4UUN3ME2yPE42PjVzIN88US=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
MHH-ES-1 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNzLkm0NUDPxE1? NVLBbJJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HCC1419 NWDCeYZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7vVYduUUN3ME2zNk4yOTF7IN88US=> M2PPWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HOP-62 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN{LkK3NFEh|ryP MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
AM-38 NH;qO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN{Lkm5N|Eh|ryP NU\sRlJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-H2009 NELEbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3e|VwUUN3ME2zN{41ODB5IN88US=> NX70PYdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
EM-2 NH3ydWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TsXmlEPTB;M{OuOVUyOSEQvF2= Mny0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
SW1116 M1LXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\rTWM2OD1|ND60PFM5KM7:TR?= M4\ndlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SK-N-AS NGfG[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN3LkC3NVQh|ryP MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
ChaGo-K-1 NYrJZXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN3Lk[wN|Ih|ryP M2m0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
RT-112 NWXiPHRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDoe5hKSzVyPUO1Mlk5PzlizszN NWjGNGJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HTC-C3 NIHhSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDyTWM2OD1|Nj6yN|U2KM7:TR?= NHTKNW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
SK-NEP-1 NWjUOmVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqyfY9OUUN3ME2zOk43OTB4IN88US=> M3y5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
LB831-BLC MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN5Lk[1OFEh|ryP NX7HT2ZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
CTB-1 NXPtWnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f6Z2lEPTB;M{iuOFUyOiEQvF2= Ml;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MOLT-4 NVjDbIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf1OIF7UUN3ME2zPE45OzlzIN88US=> M3PGVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SW756 NWLZO|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDOTWM2OD12MD65N|g2KM7:TR?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
CAL-72 NISz[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR{LkCzJO69VQ>? MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KNS-62 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfGb|U3UUN3ME20Nk43Ojl4IN88US=> MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KARPAS-299 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTzXHVvUUN3ME20N{4{OjN|IN88US=> NYLQdphURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HEL Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR3LkS2OFYh|ryP NF3hTWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KP-4 NX7Ud5dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\Cc2lEPTB;NE[uO|M3OSEQvF2= MlHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NEC8 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR5LkG2OlEh|ryP MnS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
G-402 NXfscolCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu1SIdKSzVyPUS4MlcxOTJizszN Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
Sf21 NFPtR2xHfW6ldHnvckBie3OjeR?= NEHvXZhDcW6maX7nJIFn\mmwaYT5JJRwKHerbHSgeJlx\SCqdX3hckBjcW:2aX6gcIFj\WyuZXSgdFM5KGGucHjhJEg6KHSxIEO1NkBz\XOrZIXld{kh\XiycnXzd4VlKGmwIIPmNlEhcW6|ZXP0JINmdGy|IGPQVkBidmGueYPpd{whU2RiPTCwMlAxODF{MzFOwG0v NGLERlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOFQ{OSd-Mki4N|Q1OzF:L3G+
THP1 M2\JXWZ2dmO2aX;uJIF{e2G7 MX7Jcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIGTOSoFteGijIIDyc4R2[3Srb36gbY4hcHWvYX6gWGhROSClZXzsd{whUUN3MDC9JFAvODF|IN88UU4> M3OxdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{K1O|Y5Lz5zOEOyOVc3QDxxYU6=
U937 M1rFe2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MYeyJIhzew>? Mo[2RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBlcW[oZYLlcpRq[XSnZDDoeY1idiCXOUO3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBxemWrbnP1ZoF1\WRiZn;yJFIhcHK|IH\vcIxwf2WmIHL5JGxRWy2|dHnteYxifGmxbjDmc5IhPCCqcoOgZpkhe2GwZIfpZ4ghTUyLU1GgdoVt[XSrdnWgeI8hfmWqaXPs[U11emWjdHXkJINwdnS{b3ysJGlEPTBiPTCwMlAyPSEQvF2u NWrYOHRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NFA{ODlpPkK2PFAxOzB7PD;hQi=>
THP1 Mk\PSpVv[3Srb36gZZN{[Xl? NYi3VW5JUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKGmwIHj1cYFvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxPEDPxE1w Mn74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl|NU[5NlkoRjF7M{W2PVI6RC:jPh?=
THP1 MlnySpVv[3Srb36gZZN{[Xl? MkXXTY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDD0eY1weiCwZXPyc5NqeyCoYXP0c5Iu[WyyaHGgLHRPTi2jbIDoZUkheHKxZIXjeIlwdiCrbjDUTHAuOSClZXzsd{whTUN3MDC9JFAvODF6IN88UU4> NUjBU2VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKwPFY1QDVpPkGyNFg3PDh3PD;hQi=>
THP Mn:wSpVv[3Srb36gZZN{[Xl? MoXnWIV{fGWmIH\vdkBqdmirYnn0bY9vKG:oIGT1cY9zKG6nY4Lvd4l{KG[jY4Tvdkwh[WyyaHGgbY4hXEiSIHPlcIx{NCCHQ{WwJF0hOC5yMUig{txONg>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV4MUC4O{c,OTR3NkGwPFc9N2F-
THP1 NEGxXm5HfW6ldHnvckBie3OjeR?= Mlu2TY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmZidHCqYTDwdo9lfWO2aX;uJIlvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxPEDPxE1w NGTpZok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2NFExQCd-MUe1OlAyODh:L3G+
THP1 NEHw[YhHfW6ldHnvckBie3OjeR?= MlPqTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKGmwIHj1cYFvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxPEDPxE1w MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4Mkm0NEc,OTh2NkK5OFA9N2F-
HLF NF\nUG9HfW6ldHnvckBie3OjeR?= NGXq[XpKdmirYnn0bY9vKG:oIICzPIFteGijIIDoc5NxcG:{eXzheIlwdiCrbjDJUE0yNWGucHjhMZN1cW23bHH0[YQhUEyIIHPlcIx{NCCLQ{WwJF0hOC5yNEeg{txONg>? M37lNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkCyNlYzLz5zOE[wNlI3OjxxYU6=
HLF NVq2SnJMTnWwY4Tpc44h[XO|YYm= MojrTY5pcWKrdHnvckBw\iCKU2CyO{BxcG:|cHjvdplt[XSrb36gbY4hUUxvMT3hcJBp[S2|dHnteYxifGWmIFjMSkBk\WyuczygTWM2OCB;IECuNFU5KM7:TT6= M{XqRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkCyNlYzLz5zOE[wNlI3OjxxYU6=
HEK293F NHzHdZdHfW6ldHnvckBie3OjeR?= MmDBTY5pcWKrdHnvckBw\iC|b3TpeY0h[XK|ZX7heIUh[WO2aY\heIVlKE5vdHXycYlv[WxiR2PUMZRi\2enZDDCdpVocWFibXHsZZlqKE2SS{Gg[ZhxemW|c3XkJIlvKEiHS{K5N2Yh[2WubIOgeZNqdmdiRlHNMZA{QHSrZHWgZZMhe3Wkc4TyZZRmKGK7IFnNRXAh[XO|YYmsJGlEPTBiPTCwMlE1KM7:TT6= NYjue5FrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PjJpPkK5OVQyOzZ{PD;hQi=>
BL21(DE3) MlHVSpVv[3Srb36gZZN{[Xl? NHXTcXRKdmirYnn0bY9vKG:oIICzPIFteGijIHHjeIl3\SCob4LtJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCKVGLGJIF{e2G7LDDJR|UxKD1iMD6yOUDPxE1w NIfYVVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmyPFg2QCd-MUm5Nlg5PTh:L3G+
whole blood cells MkXPRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? Mkj5OEBpenN? NF;NO5lCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKGi3bXHuJJdpd2ynIHLsc49lKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhXE6IYXzwbIEheHKxZIXjeIlwdiCjZoTldkA1KGi{czDifUB1cW2nLYLld49tfmWmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuOkDPxE1w NIr2R3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0PVI5Oid-MkK3OFkzQDJ:L3G+
A673 NXnnU2pOeUiWUzDhd5NigQ>? Mkm1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? NH72WFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY M{\XN5FJXFNiYYPzZZk> M4\yTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| NUHVWplLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD NVXlPXFJeUiWUzDhd5NigQ>? M4K5ZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NYPGSo5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M2HlbZFJXFNiYYPzZZk> NXfRS5VseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> M1\SeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NX3KO|lyeUiWUzDhd5NigQ>? MoSwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NWX1cHZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NVvwXJJKeUiWUzDhd5NigQ>? M3PieJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NEf3NVZyUFSVIHHzd4F6 M{PmUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NGm5VVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Assay
Methods Test Index PMID
Western blot p-p38 / p38 ; mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; p-p38 / γ-H2AX 23349819 26844273 27082306
In vivo BIRB 796 (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. [1] BIRB 796 has good pharmacokinetic performance even after oral administration in mice. [2]

Protocol (from reference)

Animal Research:

[2]

  • Animal Models: Collagen-induced arthritis in female Balb/c mice
  • Dosages: 1 mg/kg (intravenous) or 10 mg/kg (oral)
  • Administration: Intravenous injection or by oral
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(189.51 mM)
Ethanol 100 mg/mL
(189.51 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.

5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 527.66
Formula

C31H37N5O3

CAS No. 285983-48-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02211885 Completed Drug: 14C-BIRB 796 BS Healthy Boehringer Ingelheim October 2002 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Doramapimod (BIRB 796) | Doramapimod (BIRB 796) supplier | purchase Doramapimod (BIRB 796) | Doramapimod (BIRB 796) cost | Doramapimod (BIRB 796) manufacturer | order Doramapimod (BIRB 796) | Doramapimod (BIRB 796) distributor